Teva Pharmaceutical Industries Limited

Teva Pharmaceuticals Usa, Inc.

Other

Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag

Valerie Niddam-Hildesheim

Greta Sterimbaum

Shlomit Wizel

Kobi Chen

Natalia Shenkar

Sigalit Levi

Ehud Amir

Anna Balanov

Judith Aronhime

Ben-Zion Dolitzky

Tamar Nidam

Tamas Koltai

Maytal Piran

Neomi Gershon

Irena Veinberg

Sharona Shachan-Tov

Hagit Eisen-Nevo

Adi Yeori

Shay Asis

David Malcolm Crowe

Claude Singer

Gennady Nisnevich

Revital Lifshitz-Liron

Vinod Kumar Kansal

Csaba Szabo

Boris Pertsikov

Gideon Pilarski

Boris Tishin

Marina Etinger

Eduard Schwartz

Evgeny Shapiro

Michael Yuzefovich

Ronit Yahalomi

Rami Lidor-Hadas

Eli Lancry

Harish Ranjan

Lorant Gyuricza

Dina Blasberger

Shalom Shabat

Omer Malachi

Iamas Koltai

Szabolcs Szoke

Appu Ekambaram Ponnuswamy

Sunil Rokad

Surat Kiran

Debashish Das

Crystalline forms of Nilotinib HCl are described.

Nilotinib HCl crystalline forms

Provided are crystalline forms of O-desmethylvenlafaxine fumarate, methods for their preparation, and pharmaceutical compositions thereof.

Crystal forms of O-desmethylvenlafaxine fumarate

The present invention provides rosuvastatin and intermediates thereof having a low level of alkylether impurity and processes for the preparation thereof.

Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof

The present invention provides a crystalline form of rosuvastatin calcium characterized by an X-ray powder diffraction pattern having peaks at about 4.7, 19.4 and 22.3&#xb0; 2&#x3b8;&#xb1;0.2&#xb0; 2&#x3b8;. The crystalline form of the invention may be further characterized by a DSC thermogram with an endotherm at about 132&#xb0; C. and another broad endotherm at about 220&#xb0; C. to about 240&#xb0; C., and a TGA thermogram showing a weight loss of about of 3 to about 5 percent up to about 100&#xb0; C. The invention also provides a pharmaceutical composition comprising the crystalline rosuvastatin calcium, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.

Crystalline rosuvastatin calcium and compositions thereof for treatment of hyperlipidaemia

Provided are processes for the purification of a pure rosuvastatin intermediate by thin film evaporation and chemical method, and conversion of the intermediate to rosuvastatin or salts thereof.

Purification of rosuvatatin intermediate by thin film evaporation and chemical method

Provided is a crystalline rosuvastatin intermediate and processes for preparation thereof.

Crystalline rosuvastatin intermediate

Provided is a rosuvastatin triol and its use as a reference standard for analysis of rosuvastatin. Also provided are methods for preparation of rosuvastatin.

Triol form of rosuvastatin and synthesis of rosuvastatin

Provided are alkyl ammonium crystalline salts of rosuvastatin that provide for purification of rosuvastatin and its pharmaceutically acceptable salts.

Crystalline ammonium salts of rosuvastatin

Methods for preparing crystalline forms of O-desmethylvenlafaxine are described.

Crystal forms of O-desmethylvenlafaxine

The present invention provides a process for the preparation of the rosuvastatin intermediate FPP-CHO and its conversion to rosuvastatin and pharmaceutically acceptable salts thereof.

Process for the preparation of rosuvstatin

The invention provides a method for preparing levofloxacin hemihydrate, comprising: The invention also provides a method of converting a levofloxacin form to levofloxacin hemihydrate, comprising storing one or more forms selected from the group consisting of Forms A, B, C, F, G and H for a sufficient time to permit the one or more forms to convert to levofloxacin hemihydrate.

Preparation of levofloxacin and hemihydrate thereof

The present invention describes processes for the preparation of O-desmethylvenlafaxine and tridesmethylvenlafaxine, which may be used as an intermediate in preparing O-desmethylvenlafaxine.

Processes for the synthesis of O-desmethylvenlafaxine

Provided is a process for preparation of amorphous form of an active pharmaceutical ingredient.

Process for preparation of amorphous form of a drug

Growing community of inventors

Ein Vered, Israel

Valerie Niddam-Hildesheim